May 2025

HSCA Statement on Recent Executive Order to Promote Domestic Production of Critical Medicines

Washington, DC (May 20, 2025) – The Healthcare Supply Chain Association (HSCA), which represents the nation’s leading healthcare group purchasing organizations (GPOs), today released the following statement from President and CEO Angie Boliver regarding the recent Executive Order on Regulatory Relief to Promote Domestic Production of Critical Medicines:

“HSCA and its traditional healthcare group purchasing organization (GPO) members applaud the Trump Administration’s recent Executive Order on Regulatory Relief to Promote Domestic Production of Critical Medicines. HSCA has long advocated for policymakers to encourage investments in manufacturing capacity and quality, which are of critical importance for hospitals and the patients they serve. We support the Administration’s efforts to align foreign manufacturing facility inspections with those conducted domestically, including by increasing the fees for and number of inspections. Moreover, HSCA supports the order’s provisions focused on streamlining the permitting and construction of domestic manufacturing facilities. Expediting the building process for pharmaceutical manufacturing sites will help suppliers scale up domestic production quickly. We hope to continue working with the Administration on its domestic production objectives moving forward.”

Click here to view the full statement.

HSCA Response to the U.S. Department of Commerce’s Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients

On behalf of the Healthcare Supply Chain Association (HSCA), which represents the nation’s leading traditional healthcare group purchasing organizations (GPOs), we appreciate the opportunity to provide comments to the U.S. Department of Commerce on its Section 232 national security investigation into pharmaceutical imports.

Click here to view the full response.